NASH Observatory

⏿ The PanNASH Initiative is an interactive web-based platform presenting global NASH statistics to inform NASH control and research.

Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence?

Authors: Purssell H, Whorwell PJ, Athwal VS, et al.
Published in World J Hepatol 2021
Recently, there has been interest in the apparent co-incidence of NAFLD in patients with IBS mainly driven by improved understanding of their shared risk factors and pathophysiology H. Purssell et al. (Manchester University NHS Foundation Trust, UK)......
Read MoreNon-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence?

Non-invasive risk stratification in NAFLD/NASH patients for screening esophagogastroduodenoscopy

Authors: J, Abdelfattah T, Manka PP, et al.
Published in Clin Exp Gastroenterol 2022
J. Romano et al. (Medical University of South Carolina, Charleston, USA) evaluated whether these non-invasive markers and/or any other clinical parameters may be used to identify patients with liver cirrhosis who are likely to have large....
Read MoreNon-invasive risk stratification in NAFLD/NASH patients for screening esophagogastroduodenoscopy

Chronopharmacology, or timing of drug administration in NASH

Authors: Marjot T, Ray DW, Tomlinson JW.
Published in J Hepatol 2022
Liver homeostasis is strongly influenced by the circadian clock. Disruption of the clock has been heavily implicated in the pathogenesis of NAFLD and NASH. There has been little consideration of the application of chronopharmacology in NASH, a strategy whereby.....
Read MoreChronopharmacology, or timing of drug administration in NASH

A Nutritional Approach Increase Vegetable Consumption in NAFLD Patients

Authors: Sugiyama H, Kobayashi Y, Sumida Y, et al.
Published in J Clin Biochem Nutr 2022
The aim of this study was to investigate whether a nutritional intervention motivating increased vegetable consumption would be an effective treatment and diet therapy for patients with non-alcoholic fatty liver disease. During the 6-month intervention .....
Read MoreA Nutritional Approach Increase Vegetable Consumption in NAFLD Patients

Obese and overweight children: screening for early diagnosis of NAFLD is essential

Authors: Thiagarajan S, Shrinuvasan S, Arun Babu T.
Published in Indian J Gastroenterol 2022
NAFLD is increasingly recognised in obese and overweight children. In this cross-sectional study, S. Thiagarajan et al. (Indira Gandhi Medical College and Research Institute, India) aimed to assess the prevalence of NAFLD in this population and to identify the associated....
Read MoreObese and overweight children: screening for early diagnosis of NAFLD is essential

NAFLD/NASH: a novel pro-carcinogenic contribution for oncostatin M

Authors: Di Maira G, Foglia B, Napione L, et al.
Published in J Pathol 2022
Oncostatin M is a pleiotropic cytokine of the interleukin (IL)-6 family that contributes to the progression of chronic liver disease. G. Di Maira et al. (University of Firenze, Italy) aimed to investigate the role of oncostatin M in the development and progression of hepatocellular.....
Read MoreNAFLD/NASH: a novel pro-carcinogenic contribution for oncostatin M

5Th Global Nash Congress

5Th Global Nash Congress
Authors: https://player.vimeo.com/video/718647825
This slides set presents a detailed review of vascular alterations in non-alcoholic steatohepatitis (NASH) and NASH cirrhosis delivered by Professor Francque, MD, PhD. He highlights that non-fibrotic non-alcoholic fatty liver disease (NAFLD) is accompanied by a significant rise in portal pressure. Professor Francque, also explains the effects of intrahepatic vascular resistance increase in NAFLD. To the clinicians, he provides various patient studies, statistics and clinical data on the subject.
Read More5Th Global Nash Congress

Weight-loss alone may not be sufficient to reverse advanced fibrosis

Authors: Pais R, Aron-Wisnewsky J, Bedossa P, et al.
Published in Hepatology 2022
R. Pais et al. (Hôpital Pitié-Salpêtrière, Paris, France) describe the histological outcome in patients with advanced NASH and its relationship with weight loss and metabolic improvement after bariatric surgery. For the authors, “while bariatric surgery successfully...
Read MoreWeight-loss alone may not be sufficient to reverse advanced fibrosis

Going beyond the liver in NAFLD/NASH: hepatologist’s / endocrinologist’s perspective

pannash Webinar -2
Authors: https://player.vimeo.com/video/713587208
This multidisciplinary discussion on the diabetologist's and hepatologist's perspectives of non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH), involves international experts, Dr. Maarten Tushuizen, Prof. A.G (Onno) Holleboom and Prof. Christophe Moreno, together with the chair, Professor Manuel Castor Cabezas. The review addresses NAFLD as a multisystem disease, its epidemiology globally and the significance of developing multidisciplinary care paths.
Read MoreGoing beyond the liver in NAFLD/NASH: hepatologist’s / endocrinologist’s perspective

MAFLD might cause structural damage to brain cells

Authors: Nucera S, Ruga S, Cardamone A, et al.
Published in Sci Rep 2022
MAFLD might be considered as a multisystem disease that affects not only the liver but involves wider implications, relating to several organs and systems, the brain included.The present study by S. Nucera et al. (University Magna Graecia of Catanzaro, Italy) ...
Read MoreMAFLD might cause structural damage to brain cells

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES